Showing 1501-1510 of 1644 results for "".
- New Study Uncovers Novel Link Between Football Players, CTE, and Health Problemshttps://practicalneurology.com/news/new-study-uncovers-novel-link-between-football-players-cte-and-health-problems/2470605/Study results published in JAMA Neurology showed that approximately one-third of living former professional American-style football (ASF) players believe they have chronic traumatic encephalopathy (CTE), and this perception is associated with a higher prevalence of suicidality
- Novel DBS Approach Shows Promise for Long-Term Essential Tremor Controlhttps://practicalneurology.com/news/novel-dbs-approach-shows-promise-for-long-term-essential-tremor-control/2470599/A novel deep brain stimulation (DBS) treatment specifically targeting the dentato-rubro-thalamic tract (DRTt) was associated with statistically significant improvements in tremor control for patients with refractory essential tremor (ET) according to study results presented at the 2024 Internatio
- ANA Announces 2024 Scientific Award Winnershttps://practicalneurology.com/news/ana-announces-2024-scientific-award-winners/2470558/The American Neurological Association (ANA) has announced the recipients of their 2024 scientific awards, which will be presented at the organization’s 149th Annual Meeting in September in Orlando, Florida. The awards are intended to honor leaders in the field who have made contributions to
- GLP-1 Agonist Slows Brain Volume Loss and Cognitive Decline in People with Alzheimer Diseasehttps://practicalneurology.com/news/glp-1-agonist-slows-brain-volume-loss-and-cognitive-decline-in-people-with-alzheimer-disease/2470541/Treatment for people with mild Alzheimer disease (AD) using liraglutide, a glucagon-like peptide 1 (GLP-1) agonist, was associated with slower brain volume loss and cognitive decline vs placebo. The results from a phase 2b clinical trial were presented at the 2024 meeting of the Alzheimer’s
- Promising Results for Novel Sigma-1 Receptor Therapy as Alzheimer Treatmenthttps://practicalneurology.com/news/novel-sigma-1-receptor-therapy-slowed-clinical-progression-in-alzheimer-disease/2470543/Treatment with Anavex2-73 (blarcamesine; Anavex Life Sciences, New York, NY) for people with early Alzheimer disease (AD) was associated with slowed clinical progression in cognitive and functional outcomes. Anavex2-73 is a small-molecule activator of the sigma-1 receptor (SIGMAR1) that is orally
- American Football Participation Linked to Parkinsonism Risk in People with CTEhttps://practicalneurology.com/news/american-football-participation-linked-to-parkinsonism-risk-in-people-with-cte/2470532/Parkinsonism was prevalent among deceased contact sports participants with chronic traumatic encephalopathy (CTE) and was associated with repetitive head impacts (RHIs), substantia nigra (SN) Lewy bodies (LBs), neurofibrillary tangles (NFTs), dopaminergic neuronal loss, and age at death. The resu
- Riliprubart Treatment Provides Disease-Controlling Benefits in CIDPhttps://practicalneurology.com/news/riliprubart-treatment-provides-disease-controlling-benefits-in-cidp/2470525/Treatment with riliprubart (Sanofi, Bridgewater, NJ) for people with chronic inflammatory demyelinating polyneuropathy (CIDP) was associated with disease-controlling benefits, even for those who experienced failure, inadequate response, or residual disability when treated with standard of care (S
- Mounjaro Improved Obstructive Sleep Apnea Outcomeshttps://practicalneurology.com/news/mounjaro-improved-obstructive-sleep-apnea-outcomes/2470521/For people with moderate-to-severe obstructive sleep apnea (OSA) and obesity, treatment with Mounjaro (tirzepatide; Lilly, Indianapolis, IN) was associated with reduced apnea-hypopnea index (AHI), body weight, hypoxic burden, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic
- Investigational Therapy for Facioscapulohumeral Muscular Dystrophy Shows Promise According to Avidity Bioscienceshttps://practicalneurology.com/news/investigational-therapy-for-facioscapulohumeral-muscular-dystrophy-shows-promise-according-to-avidity-biosciences/2470511/Initial 4-month results from the phase 1/2 FORTITUDE clinical trial (NCT05747924) reveal that treatment of people with facioscapulohumeral muscular dystrophy (FSHD) using AOC 1020 (delpacibart braxlosiran [del-brax]; Avidity Biosciences, San Diego, CA) is associated with functional improvement an
- Lifestyle Changes Improved Cognition, Function, Aβ Biomarkers in People with Early Alzheimer Disease According to RCThttps://practicalneurology.com/news/lifestyle-changes-improved-cognition-function-av-biomarkers-in-people-with-early-alzheimer-disease-according-to-rct/2470499/Lifestyle changes, including diet, exercise, stress management, and participation in support groups, were associated with improved cognition and function in people with mild cognitive impairment (MCI) or early dementia due to Alzheimer disease (AD). People who received usual care showed no improv